WO2021206360A1 - 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 - Google Patents
토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 Download PDFInfo
- Publication number
- WO2021206360A1 WO2021206360A1 PCT/KR2021/003989 KR2021003989W WO2021206360A1 WO 2021206360 A1 WO2021206360 A1 WO 2021206360A1 KR 2021003989 W KR2021003989 W KR 2021003989W WO 2021206360 A1 WO2021206360 A1 WO 2021206360A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- botulinum toxin
- formulation
- syringe
- liquid formulation
- barrel
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 144
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 141
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims description 124
- 238000009472 formulation Methods 0.000 claims description 97
- 239000012669 liquid formulation Substances 0.000 claims description 78
- 239000000463 material Substances 0.000 claims description 49
- 229940071643 prefilled syringe Drugs 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 238000011084 recovery Methods 0.000 claims description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 229920005549 butyl rubber Polymers 0.000 claims description 15
- 239000005062 Polybutadiene Substances 0.000 claims description 14
- 229920002857 polybutadiene Polymers 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 229920003049 isoprene rubber Polymers 0.000 claims description 12
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 11
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229940068977 polysorbate 20 Drugs 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 9
- 229920005555 halobutyl Polymers 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 7
- 239000007995 HEPES buffer Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 5
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 5
- 229940101027 polysorbate 40 Drugs 0.000 claims description 5
- 229940113124 polysorbate 60 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 29
- 238000000576 coating method Methods 0.000 description 29
- 239000011248 coating agent Substances 0.000 description 28
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 27
- 229920005557 bromobutyl Polymers 0.000 description 24
- -1 polydimethylsiloxane Polymers 0.000 description 23
- 238000003860 storage Methods 0.000 description 21
- 231100000636 lethal dose Toxicity 0.000 description 20
- 229920005556 chlorobutyl Polymers 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 230000001133 acceleration Effects 0.000 description 18
- 229920001971 elastomer Polymers 0.000 description 18
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 239000004447 silicone coating Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 12
- 239000005060 rubber Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 229920001296 polysiloxane Polymers 0.000 description 11
- 239000013536 elastomeric material Substances 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004809 Teflon Substances 0.000 description 9
- 229920006362 Teflon® Polymers 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- 231100000189 neurotoxic Toxicity 0.000 description 8
- 230000002887 neurotoxic effect Effects 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 6
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229920000052 poly(p-xylylene) Polymers 0.000 description 6
- 229920002545 silicone oil Polymers 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 239000000806 elastomer Substances 0.000 description 5
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 5
- 239000012632 extractable Substances 0.000 description 5
- 239000012633 leachable Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 4
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 4
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 229940094657 botulinum toxin type a Drugs 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 4
- 229920009441 perflouroethylene propylene Polymers 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229920002620 polyvinyl fluoride Polymers 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229920001038 ethylene copolymer Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004446 fluoropolymer coating Substances 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- KHXKESCWFMPTFT-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-(1,2,2-trifluoroethenoxy)propane Chemical compound FC(F)=C(F)OC(F)(F)C(F)(F)C(F)(F)F KHXKESCWFMPTFT-UHFFFAOYSA-N 0.000 description 2
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 description 2
- VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002174 Styrene-butadiene Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000005011 phenolic resin Substances 0.000 description 2
- 238000000623 plasma-assisted chemical vapour deposition Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000012858 resilient material Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108700014852 coretox Proteins 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007152 ring opening metathesis polymerisation reaction Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31573—Accuracy improving means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M2005/3131—Syringe barrels specially adapted for improving sealing or sliding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Definitions
- the present invention relates to a botulinum toxin prefilled syringe formulation that is easy to control and is stable in dispensing rate.
- Botulinum toxin (BoNT) is one of the most potent toxins known and works by blocking the release of acetylcholine from peripheral cholinergic neurons. Botulinum toxin has been used to reduce overactive muscles and exocrine glands by administering very small doses to the subject. For example, botulinum toxin is used for cosmetic purposes as well as for the treatment of neuromuscular diseases and hyperactive exocrine diseases.
- Botulinum toxin is inherently labile, in particular it is known to be highly labile and heat-labile at alkaline pH.
- a medical dosage form that overcomes these shortcomings is the prefilled syringe, which has become increasingly popular as a drug delivery device in recent years.
- the protein's limited stability makes it a particularly difficult task for formulation scientists to use the prefilled syringe method. In particular, this applies to very dilute aqueous solutions of botulinum toxin.
- stabilizing proteins such as human serum albumin (HSA) are often added. It is also known to add non-proteinaceous stabilizers, such as surfactants, polyvinylpyrrolidone (PVP), disaccharides, polyols and the like.
- non-proteinaceous stabilizers such as surfactants, polyvinylpyrrolidone (PVP), disaccharides, polyols and the like.
- One aspect is to provide a botulinum toxin prefilled syringe formulation that is easy and stable to control the syringe ejection rate.
- One aspect provides a botulinum toxin prefilled syringe formulation comprising a syringe comprising a syringe barrel, a plunger rod and a plunger stopper, and a botulinum toxin liquid formulation filled within the syringe.
- the amount of increase in the force acting on the end of the plunger rod may decrease as the rate at which the botulinum toxin liquid formulation is discharged increases.
- filled syringe means that it can be sealed or has a sealed, partially or completely enclosed space that can be used to receive, store, and/or transport a liquid formulation. indicates a syringe.
- Said syringe refers to a closed or sealed container made of plastic, such as an organic polymer, or partially or predominantly made of plastic.
- the prefilled syringe has two openings that are sealed to prevent leakage of the contents.
- the prefilled syringe has a proximal end sealed by a plunger stopper and a distal end sealed by a capping device.
- the barrel may include a proximal end and a distal end and a generally cylindrical wall extending therebetween and defining a barrel lumen.
- the barrel may have a distally projecting tip extending therethrough and having a fluid passageway in communication with the barrel lumen.
- the proximal and distal ends each have a proximal end open outlet and a distal end open outlet.
- the tip may have the same material as the rest of the barrel.
- the barrel may be, after filling, by a capping device for sealingly closing the distal end of the syringe (e.g., a “tip cap” that is removed prior to use and replaced with a needle, or a prefill with a removable or permanent needle).
- a capping device for sealingly closing the distal end of the syringe (e.g., a “tip cap” that is removed prior to use and replaced with a needle, or a prefill with a removable or permanent needle).
- a sealing means such as a needle shield in the case of a closed syringe
- the tip cap, needle shield or other type of capping device remove the tip cap, needle shield or other type of capping device, optionally attach a needle (if not already present), and advance the plunger tip or piston within the barrel to determine the contents of the barrel.
- the botulinum toxin preparation is injected into the patient.
- the inner surface of the barrel may or may not be coated.
- the inner surface of the barrel may be coated, for example, with a barrier layer for lubrication purposes (hereinafter also referred to as "lubricant layer").
- the lubricant layer should not only provide a high lubricity to allow the plunger to easily glide through the barrel, but should also be compatible with the botulinum toxin formulation and ensure its shelf life.
- the lubricant layer may be a silicone-free lubricant layer or a silicone lubricant layer.
- the inner surface of the wall may be coated with silicone. That is, the barrier layer may be a silicon layer.
- the silicone coating may be prepared by silicone oil-based methods (eg, spray-on siliconization or baked-on siliconization) and vapor deposition methods (eg, plasma enhanced chemical vapor deposition (PECVD)). )) by a siliconization method selected from The silicone coating may be formed by, for example, spray-on siliconized, or baked-on siliconized coating.
- the silicone coating may be a polydimethylsiloxane coating.
- silicone oil eg, DOW CORNING ® 360 having a viscosity of 1000 cSt
- syringe i.e., using, for example, a diving or static nozzle
- a thin layer of silicone oil can be created by spraying into the barrel.
- Baked-on siliconized method may include the application of the emulsion, for example, a silicone oil as the Dow Corning ® 365 siliconized emulsion to the barrel, and then baked on a plastic surface for a certain time at a certain temperature.
- the baked-on siliconization method can result in fewer invisible silicone oil particles and fewer visible silicone oil particles compared to the spray-on siliconization method.
- the material of the syringe barrel may include a plastic material.
- the material may be glass, COC, COP, or a mixture thereof.
- the COP may be coated with silicone on its surface.
- COC is produced by polymerization of ethane with a cyclic monomer such as norbornene, while COP can be produced by hydrogenation after ring-opening metathesis of a cyclic monomer.
- COC, COP and mixtures of COP and COC materials exhibit a number of desirable characteristics, including high transparency, low density, excellent moisture barrier ability, and resistance to aqueous and polar organic media. Specific examples include Topas ® COC and DaikyoCrystal Zenith ® .
- the tip of the barrel may be integrally formed with the barrel.
- the tip may be molded integrally with the barrel.
- the barrel may include an integrally formed luer lock tip or a luer slip tip.
- the tip may include an integral passageway extending axially through the tip and communicating with the chamber for dispensing the contents of the barrel.
- the tip may have a substantially frustoconical shape converging from the distal exit end of the barrel toward the exit end of the tip.
- the barrel may have an inner diameter adapted to accommodate a fill volume of, for example, 0.5 ml, 1.0 ml, 1.5 ml, or 2.0 ml.
- the barrel may have a graduated mark indicating the volume of fluid in the syringe.
- the barrel may include a flange-style interface.
- the design of the flange may be, for example, conforming to ISO11040.
- the flange-style interface may optionally be compatible with an existing handle.
- the ratio of the length to the inner diameter of the syringe barrel may be 10 to 22, 12 to 20, or 14 to 16.
- the syringe barrel has an inner diameter of 3 to 7 mm, 3.5 to 6.5 mm, 4 to 6 mm, or 4.5 to 5.5 mm, and a length of 30 to 130 mm, 50 to 110 mm, 60 to 100 mm, or 70 to 90 mm.
- the syringe may have an inner diameter of 3.5 to 6.5 mm and a length of 60 to 100 mm.
- the syringe may have an inner diameter of 3 to 7 mm of the barrel, and a length of 30 to 130 mm.
- the syringe may have an inner diameter of 4 to 6 mm and a length of 50 to 110 mm.
- the syringe may have an inner diameter of 4.5 to 5.5 mm, and a length of 70 to 90 mm.
- the plunger rod and the plunger stopper may be combined to form a plunger rod and a plunger stopper assembly.
- the assembly may extend into a proximal end of the barrel.
- the assembly may include a rod having a plunger stopper at its tip in sliding fluid tight engagement with the cylindrical wall of the barrel lumen.
- the assembly forms a proximal seal and a dynamic seal that allows extrusion of the botulinum toxin liquid formulation.
- the stopper is in contact with the botulinum toxin liquid formulation during storage and/or administration.
- the stopper may be made of an elastomeric material.
- the stopper may optionally have a coating on at least a portion thereof that comes into contact with the botulinum toxin liquid formulation during storage and/or injection.
- the elastomer is isoprene rubber (IS), butadiene rubber (polybutadiene, BR), butyl rubber (copolymer of isobutylene and isoprene, IIR), halogenated butyl rubber (e.g. chlorobutyl rubber, CIIR; and bromine) parent butyl rubber, BIIR), styrene-butadiene rubber (copolymer of styrene and butadiene, SBR), or mixtures thereof.
- the stopper material may be butyl rubber, halogenated butyl rubber, or a mixture thereof.
- the stopper material may be bromobutyl rubber or chlorobutyl rubber.
- the elastomer may also be reinforced with inert minerals.
- the elastomer may be cured by, for example, an organic peroxide, a phenol resin, or the like.
- the stopper may be coated or uncoated.
- the coating is typically applied to at least the seal surface, including the surface portion of the plunger stopper that faces the barrel lumen and is in contact with the botulinum toxin formulation during storage and/or use.
- the coating may provide good lubricity while minimizing interaction between the plunger stopper and the botulinum toxin liquid formulation.
- a suitable coating of the plunger stopper may generally be made of a material that does not undesirably interfere with the botulinum toxin formulation and exhibits low levels of extractables/leachables.
- the coating may be one comprising polypropylene, polyethylene, parylene (eg, Parylene N, Parylene C, and Parylene HT), crosslinked silicone, a fluoropolymer, or mixtures thereof.
- parylene eg, Parylene N, Parylene C, and Parylene HT
- crosslinked silicone coatings include B2-coating (Daikyo Seiko) or XSi TM (Becton Dickinson).
- the fluoropolymer coating may be a fluorinated ethylene-propylene copolymer (eg, tetrafluoroethylene-hexafluoropropylene copolymer (FEP)), a fluorinated ethylene-ethylene copolymer (eg, ethylene tetrafluoro Roethylene copolymers (ETFE), such as Flurotech ® ), PVA (copolymer of tetrafluoroethylene (TFE) and perfluoropropylvinyl ether (PPVE)), tetrafluoroethylene-perfluoroethylene copolymer, polyvinylidene fluoride (PVDF), polyvinyl fluoride (PVF), polytetrafluoroethylene (PTFE) (Teflon), or mixtures thereof.
- the coating is made of ETFE, in particular a Plurotech ® coating.
- the plunger stopper may be uncoated.
- the design of the plunger stopper is not particularly limited and may be a nested or bagged stopper.
- the interface to the rod may be threaded to enable installation of the rod after sterilization.
- the interface to the rod may be designed in a snap-on design.
- Rods, such as plunger stoppers, are generally designed to withstand sterilization, but are not otherwise limited in any particular way.
- the rod may be made of a plastic material such as ethylene vinyl acetate (EVA) copolymer or polypropylene.
- a pre-filled syringe contains a plunger ( 80 ) comprising a barrel ( 10 ), a plunger rod ( 20 ) and a plunger stopper ( 30 ), a needle ( 50 ) and a botulinum toxin liquid formulation ( 40 ) contained in the lumen of the barrel ( 10 ). ) is included.
- the prefilled syringe may include a “capping device”.
- the capping device broadly refers to any means for closing and sealing the distal open outlet end of a syringe.
- the term "open outlet end” or “distal open outlet end” refers to any distal open end of a syringe in fluid communication with the barrel lumen.
- the capping device may have a channel having a closed end and an open end generally dimensioned to receive and effectively seal the open outlet end of the syringe to prevent leakage.
- the capping device is a capping means commonly known as a “tip cap”.
- the tip cap forms a fluid tight seal with the tip of the syringe, effectively closing the syringe barrel and preventing leakage of the syringe barrel's contents.
- the tip cap is typically removably coupled to a syringe tip or luer collar.
- a luer collar surrounds the top of the syringe barrel (eg, syringe tip).
- the luer collar may have an internal thread and the tip cap may have an external thread complementary to the internal thread of the luer collar for coupling the tip cap to the syringe barrel.
- the luer collar is generally formed integrally with the syringe barrel.
- the tip cap Prior to use, the tip cap may be removed and then the needle cannula (needle assembly) may be securely coupled to the syringe tip.
- a prefilled syringe is a luer having a plunger 80 comprising a barrel 10, a plunger rod 20 and a plunger stopper 30, a tip 100 formed at the distal end of the barrel, and threads formed in the tip. It includes a collar 110 , a tip cap 120 fixed to the tip by coupling with the luer collar, and a botulinum toxin liquid formulation 40 contained in the lumen of the barrel 10 .
- a prefilled syringe is a removable or non-removable (i.e. permanent) cannula or needle cannula (also referred to as a “needle” or “needle assembly”) extending from a syringe tip for delivering a botulinum toxin preparation from the syringe.
- the capping device may be referred to as a "needle shield”.
- the needle shield may generally have a channel having a closed end and an open end dimensioned to receive and couple a cannula (needle) mounted on the tip of the syringe.
- the (sharp) end of the cannula may pass through the closed end of the channel in the needle shield to seal the open end of the cannula.
- the prefilled syringe comprises a plunger ( 80 ) comprising a barrel ( 10 ), a plunger rod ( 20 ) and a plunger stopper ( 30 ), a needle ( 50 ), a needle assembly ( 60 ), a needle shield ( 70 ) and the barrel ( 10 ). ) botulinum toxin liquid formulation 40 contained in the lumen.
- the capping device may be a single member and may typically be made of a flexible and resilient polymeric material (eg, elastomeric), or coupled to a flexible and resilient inner cap. It may have an outer cap made of a rigid plastic material, for example, or a material comprising or made of an elastomer, at least a portion of which contacts and seals the distal opening of the syringe. Generally, at least the outlet engagement portion that contacts the distal tip opening to form a fluid tight seal is fabricated from a flexible and/or resilient material (eg, an elastomeric material), wherein the engagement portion is botulinum toxin during storage and/or use. may come into contact with a toxin agent.
- a flexible and resilient polymeric material eg, elastomeric
- the outlet engagement portion may be made of a material that minimizes the likelihood of unwanted extractables/leachables.
- the outlet binding moiety may have a coating thereon.
- Suitable flexible and/or resilient materials of the capping device, particularly of the outlet engagement portion may include elastomers that allow long-term storage without interfering with the aqueous botulinum toxin formulation.
- the portion of the sealing device, eg the outlet engagement portion, that contacts, or is configured to contact, the botulinum toxin formulation should exhibit low extractable/leachable levels during long-term storage of the botulinum toxin formulation.
- the term "elastomeric” or “elastomeric material” refers to a crosslinked thermoset rubbery polymer that is more readily deformable than plastic but is approved for use with pharmaceutical grade fluids and does not readily leach or outgas. may include.
- the elastomeric material may include isoprene rubber (IS), butadiene rubber (polybutadiene, BR), butyl rubber (copolymer of isobutylene and isoprene; IIR), halogenated butyl rubber (eg, chloro butyl rubber, CIIR; and bromobutyl rubber: BIIR), styrene-butadiene rubber (copolymer of styrene and butadiene, SBR), or mixtures thereof.
- the elastomeric material may be butyl rubber or halogenated butyl rubber, in particular bromo butyl rubber or chloro butyl rubber, or mixtures thereof.
- the elastomeric material may also be reinforced with inert minerals. Further, the elastomeric material may be cured by, for example, organic peroxides, phenolic resins, and the like.
- a suitable coating which may optionally be present on the outlet binding portion made from the aforementioned elastomeric material, generally does not undesirably interfere with the aqueous botulinum toxin formulation and is a material that exhibits low levels of extractables/leachables.
- Coatings for use in the present invention may include polypropylene, polyethylene, parylene (eg, Parylene N, Parylene C, and Parylene HT), crosslinked silicone, or fluoropolymer coatings.
- suitable crosslinked silicone coatings include B2-coating (Daikyo Seiko) or XSiTM (Becton Dickinson).
- Fluoropolymer coatings include fluorinated ethylene-propylene copolymers (eg, tetrafluoroethylene-hexafluoropropylene copolymer (FEP)), fluorinated ethylene-ethylene copolymers (eg, ethylene tetra Fluoroethylene copolymers (ETFE) such as Flurotech®), PVA (copolymer of tetrafluoroethylene (TFE) and perfluoropropylvinyl ether (PPVE)), tetrafluoroethylene-perfluoro ethylene copolymer, polyvinylidene fluoride (PVDF), polyvinyl fluoride (PVF), polytetrafluoroethylene (PTFE), or mixtures thereof.
- the coating is made of, for example, ETFE, and may be a Flurotech ® coating.
- the botulinum toxin liquid formulation may be an aqueous formulation.
- the corrective formulations may include aqueous suspensions, aqueous dispersions, aqueous emulsions, or aqueous solutions.
- the botulinum toxin liquid formulation has a concentration of, for example, about 1 to about 3,000 U/mL, about 10 to about 1,000 U/mL, about 10 to about 400 U/mL, about 10 to about 200 U/mL , about 10 to about 100 U/mL, about 10 to about 70 U/mL, about 20 to about 60 U/mL, or about 40 U/mL.
- the dose of the botulinum toxin liquid formulation may be 10 to 80, 10 to 50, 20 to 80, 20 to 60, 20 to 50, 30 to 80, 40 to 80, 20 to 40, or 25 to 35 units/syringe. .
- botulinum toxin broadly refers to any form or type of botulinum toxin. More specifically, the botulinum toxin may be a botulinum toxin type A, B, C1, C2, D, E, F, G, or a mixture thereof. For example, the botulinum toxin may be serotype A, B or C1.
- botulinum toxin is intended to include both the botulinum toxin complex (“toxin complex”) and the “neurotoxic component” of the botulinum toxin or complex.
- botulinum toxin complex refers to a high molecular weight complex comprising a neurotoxic component of approximately 150 kDa and a non-toxic protein of Clostridium botulinum, also comprising hemagglutinin and non-hemagglutinin proteins. refers to The botulinum toxin serotype A complex may be, for example, Medytoxin (Medytox).
- neurotoxic component relates to a neurotoxic polypeptide of the toxin complex ("150 kDa" polypeptide; usually its two-chain form), free of any associated non-toxic proteins.
- the pure neurotoxic component may be, for example, Coretox Injection (Medytox).
- botulinum toxin refers to the neurotoxic component of a botulinum toxin complex of a given serotype (eg serotype A, B or Cl, in particular serotype A).
- the botulinum toxin formulation contained in the prefilled syringe may contain only the neurotoxic component and be free of any other protein of the Clostridium botulinum toxin complex.
- the botulinum toxin is a wild-type botulinum toxin, for example, at least 50%, 60% to the amino acid sequence of a neurotoxic component of a wild-type botulinum toxin A or serotype A1 botulinum toxin deposited in the GenBank database under accession number AAA23262 Functional (ie biologically active) isoforms, homologs, orthologs of botulinum toxin exhibiting sequence identity of greater than, greater than 70%, greater than 80%, or greater than 90% , a paralog, or a fragment.
- Functional ie biologically active
- Sequence identity can be calculated by any algorithm suitable for producing reliable results, for example using the FASTA algorithm (WR Pearson & DJ Lipman, PNAS 85:2444-2448, 1988). Sequence identity can be calculated by comparing two domains, such as two polypeptides, or two LC domains or fragments thereof.
- the botulinum toxin includes modified and recombinant botulinum toxin.
- the botulinum toxin liquid formulation may contain other pharmaceutically acceptable substances such as salts (eg sodium chloride), stabilizing proteins (eg albumin, gelatin), sugars (eg glucose, fructose, galactose, trehalose, sucrose and maltose), carbohydrate polymers (eg hyaluronic acid and polyvinylpyrrolidone (PVP)), polyols (eg mannitol, inositol, lactitol, isomalt, xylitol, eryth glycerol and sugar alcohols such as ritol and sorbitol), amino acids, vitamins (eg vitamin C), zinc, magnesium, anesthetics (eg, local anesthetics such as lidocaine), surfactants, tonicity modifiers, etc. may include As used herein, the term “pharmaceutically acceptable” refers to a compound or substance suitable for contact with tissue of a mammal, particularly a human.
- the botulinum toxin liquid formulation may not contain animal ingredients.
- the botulinum toxin liquid formulation may not contain albumin.
- the botulinum toxin liquid formulation may include botulinum toxin, an amino acid, a surfactant, and a tonicity adjusting agent in water.
- the botulinum toxin liquid formulation comprises, for example, 10 to 70 U/ml of botulinum toxin, 0.05 to 0.7 g/L amino acid, and 0.10 to 0.5 g/L of surfactant and 0.10 to 1.0 g/L of NaCl in water. may include.
- the botulinum toxin may be a botulinum toxin type A, B, C1, C2, D, E, F, G, or a mixture thereof.
- the amino acids are glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, arginine, histidine, aspartic acid, glutamic acid, pharmaceutically thereof acceptable salts, or mixtures thereof.
- the amino acid may be, for example, methionine, histidine, arginine, a pharmaceutically acceptable salt thereof, or a mixture thereof.
- the surfactant may be a nonionic surfactant.
- the nonionic surfactant may be a polysorbate, a poloxamer, or a mixture thereof.
- the polysorbate may be polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a mixture thereof.
- the NaCl may be added at a physiologically acceptable concentration, for example, about 0.85 to 0.95 g/L, or about 0.9 g/L.
- the botulinum toxin liquid formulation may further contain a buffer to maintain the pH at about 5.5 to about 7.5.
- the buffer may be citrate, histidine, HEPES, arginine, acetic acid, phosphoric acid, salts thereof, or a mixture thereof.
- the pH of the botulinum toxin preparation may be maintained in the range of about 5.5 to about 7.5, about 6.0 to about 7.5, about 6.5 to about 7.5, about 6.1 to about 7.3, or about 6.2 to about 7.2 during storage.
- the botulinum toxin liquid formulation exhibits an LD 50 titer recovery of 75 to 125%, 75 to 120%, or 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition. it could be
- the liquid formulation of botulinum toxin exhibits a protease activity recovery rate of 75 to 125%, 75 to 120%, or 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25°C, an accelerated test condition.
- the liquid formulation of botulinum toxin may have a pH fluctuation within ⁇ 1.5, ⁇ 1.0, or ⁇ 0.5 compared to the initial value when stored for 2, 4, or 6 months at 25°C, an accelerated test condition.
- One embodiment includes a syringe barrel, a syringe including a plunger rod and a plunger stopper, and a botulinum toxin liquid formulation filled in the syringe, wherein the distal end of the plunger rod as the rate at which the botulinum toxin liquid formulation is discharged increases It may be a botulinum toxin prefilled syringe formulation with a reduced amount of increase in the force acting on it.
- the ratio of the length to the inner diameter of the syringe barrel may be 10 to 22.
- the syringe barrel may have an inner diameter of 3.5 to 6.5 mm and a length of 60 to 100 mm.
- the material of the syringe barrel may be glass, COC, or silicone-coated COP.
- the material of the syringe barrel may be COC.
- the silicone coating may be a spray-on silicone coating, a baked-on silicone coating, or a polydimethylsiloxane coating.
- the material of the plunger stopper may be isoprene rubber (IS), butadiene rubber (BR), butyl rubber, halogenated butyl rubber, styrene-butadiene rubber, or a mixture thereof.
- the plunger stopper may be uncoated.
- the dose of the botulinum toxin liquid formulation may be 10 to 50 units/syringe.
- the botulinum toxin liquid formulation may not contain albumin.
- the botulinum toxin liquid formulation may not contain animal ingredients.
- the botulinum toxin liquid formulation may include a botulinum toxin, an amino acid, a surfactant, and an isotonic agent.
- the amino acid may be methionine.
- the surfactant may be polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or poloxamer.
- the botulinum toxin liquid formulation may further contain a buffer to maintain the pH at 5.5 to 7.5.
- the buffer may be citrate, histidine, HEPES, arginine, acetic acid, phosphoric acid, salts thereof, or a mixture thereof.
- the liquid formulation of botulinum toxin may exhibit an LD 50 titer recovery rate of 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition.
- the liquid formulation of botulinum toxin may exhibit a protease activity recovery rate of 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition.
- the botulinum toxin liquid formulation may have a pH fluctuation within ⁇ 1.0 compared to an initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition.
- Another embodiment comprises a syringe barrel, a syringe comprising a plunger rod and a plunger stopper, and a botulinum toxin liquid formulation filled in the syringe, wherein the syringe barrel is made of glass, COC, or silicone coated COP botulinum toxin prefilled syringe formulation.
- the material of the syringe barrel may be COC.
- the silicone coating may be a spray-on silicone coating, a baked-on silicone coating, or a polydimethylsiloxane coating.
- the material of the plunger stopper may be isoprene rubber (IS), butadiene rubber (BR), butyl rubber, halogenated butyl rubber, styrene-butadiene rubber, or a mixture thereof.
- the plunger stopper may be uncoated.
- the ratio of the length to the inner diameter of the syringe barrel may be 10 to 22.
- the syringe barrel may have an inner diameter of 3.5 to 6.5 mm and a length of 60 to 100 mm.
- the dose of the botulinum toxin liquid formulation may be 10 to 50 units/syringe.
- the botulinum toxin liquid formulation may not contain albumin.
- the botulinum toxin liquid formulation may not contain animal ingredients.
- the botulinum toxin liquid formulation may include a botulinum toxin, an amino acid, a surfactant, and an isotonic agent.
- the amino acid may be methionine.
- the surfactant may be polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or poloxamer.
- the botulinum toxin liquid formulation may further contain a buffer to maintain the pH at 5.5 to 7.5.
- the buffer may be citrate, histidine, HEPES, arginine, acetic acid, phosphoric acid, salts thereof, or a mixture thereof.
- the botulinum toxin liquid formulation may exhibit an LD 50 titer recovery rate of 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition.
- the liquid formulation of botulinum toxin may exhibit a protease activity recovery rate of 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25° C., which is an accelerated test condition.
- the botulinum toxin liquid formulation may have a pH fluctuation within ⁇ 1.0 compared to an initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition.
- Another embodiment includes a syringe comprising a syringe barrel, a plunger rod and a plunger stopper, and a botulinum toxin liquid formulation filled within the syringe, wherein the botulinum toxin liquid formulation does not contain albumin. It may be in the form of a syringe.
- Botulinum toxin comprising a syringe barrel, a syringe comprising a plunger rod and a plunger stopper, and a botulinum toxin liquid formulation filled in the syringe, wherein the botulinum toxin liquid formulation does not contain an animal component It may be in the form of a prefilled syringe.
- the botulinum toxin liquid formulation may include a botulinum toxin, an amino acid, a surfactant, and an isotonic agent.
- the amino acid may be methionine.
- the surfactant may be polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or poloxamer.
- the botulinum toxin liquid formulation may further contain a buffer to maintain the pH at 5.5 to 7.5.
- the buffer may be citrate, histidine, HEPES, arginine, acetic acid, phosphoric acid, salts thereof, or a mixture thereof.
- the dose of the botulinum toxin liquid formulation may be 10 to 50 units/syringe.
- the material of the syringe barrel may be glass, COC, or silicone-coated COP.
- the material of the syringe barrel may be COC.
- the silicone coating may be a spray-on silicone coating, a baked-on silicone coating, or a polydimethylsiloxane coating.
- the material of the plunger stopper may be isoprene rubber (IS), butadiene rubber (BR), butyl rubber, halogenated butyl rubber, styrene-butadiene rubber, or a mixture thereof.
- the plunger stopper may be uncoated.
- the amount of increase in the force acting on the end of the plunger rod may decrease as the rate at which the botulinum toxin liquid formulation is discharged increases.
- the ratio of the length to the inner diameter of the syringe barrel may be 10 to 22.
- the syringe barrel may have an inner diameter of 3.5 to 6.5 mm and a length of 60 to 100 mm.
- the liquid formulation of botulinum toxin may exhibit an LD 50 titer recovery rate of 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25° C., which is an accelerated test condition.
- the liquid formulation of botulinum toxin may exhibit a protease activity recovery rate of 80 to 125% compared to the initial value when stored for 2, 4, or 6 months at 25°C, an accelerated test condition.
- the liquid formulation of botulinum toxin may have a pH fluctuation within ⁇ 1.0 compared to an initial value when stored for 2, 4, or 6 months at 25° C., an accelerated test condition.
- the LD 50 titer, the botulinum toxin endopeptidase titer, and pH can be kept stable.
- it is easy to control the discharge rate according to the botulinum toxin pre-filled syringe formulation.
- FIG. 1 is a view showing an example of a prefilled syringe including a needle.
- FIG. 2 is a view showing an example of a prefilled syringe including a tip cap.
- FIG. 3 is a diagram illustrating an example of a prefilled syringe including a needle assembly and a needle shield.
- Example 1 Stability of Botulinum Toxin Prefilled Liquid Syringe Formulation: Syringe with Barrel Made of COC or COP Material
- a liquid botulinum toxin preparation was filled in a syringe for use in a highly viscous drug (HVD) (hereinafter also referred to as 'HVD syringe'), and stability according to the storage period was measured.
- HVD highly viscous drug
- the HVD syringe had an inner diameter of 5.00 mm, an outer diameter of 9.40 mm, a barrel length of 80.0 mm, and a volume to be filled with the liquid formulation of 0.8 mL.
- SCHOTT's TopPac TM syringe has an inner diameter of 6.50 mm, an outer diameter of 9.40 mm, a barrel length of 64.5 mm, and a volume filled with a liquid formulation of 1 mL. That is, the HVD syringe has a smaller inner diameter and a longer length than the TopPac TM syringe.
- the TopPac TM syringe includes a barrel, plunger, plunger rod and tip cap, the barrel is made of COC material and has a Luer Lock. The inner surface of the barrel is crosslinked by curing after siliconization with a reactive silicone mixture.
- the tip cap is made of rubber (Datwyler).
- HVD syringe contains COC material made of TOPAS 6015 material and has improved heat resistance.
- the syringe includes a plastic syringe barrel, a capping device, and a plunger rod assembly.
- the barrel includes a proximal end and a distal end and a generally cylindrical wall extending therebetween and defining a barrel lumen.
- the barrel has a distally projecting tip extending therethrough and having a fluid passageway in communication with the barrel lumen, the generally cylindrical wall having an interior surface optionally coated with a barrier layer.
- the inner surface of the wall is coated with silicone, ie the barrier layer is a silicone layer.
- the barrel has a COC or COP material.
- the capping device has an outlet engagement portion sealingly engaging and closing the open outlet of the distal end of the barrel.
- the capping device for the distal end of the barrel consists of a cap and a rubber tip cap, the cap being made of polycarbonate material, and the rubber tip cap being made of the same material as the plunger.
- the rubber tip cap corresponds to the outlet coupling portion.
- the outlet engaging portion is made of an elastomeric material having an optional coating on its surface. The outlet coupling portion and the capping device are coupled in a luer-lock configuration.
- the plunger rod assembly extends into the proximal end of the barrel and includes a plunger stopper in sliding fluid-tight engagement with the cylindrical wall of the barrel lumen, the stopper being made of an elastomeric material, the stopper being during storage and/or injection. optionally having a coating on at least a portion of said stopper in contact with the aqueous liquid botulinum toxin formulation.
- the material of the stopper is bromobutyl rubber (BIIR) or chlorobutyl rubber (CIIR), which are optionally coated with Teflon.
- Table 1 shows a botulinum toxin prefilled syringe formulation prefilled with a liquid botulinum toxin formulation in water used in this example.
- Formulation name A B C D E F G H barrel material COC COC COC COC COC COC COC COP COP plunger stopper material BIIR BIIR BIIR BIIR CIIR CIIR CIIR plunger stopper coating does not exist does not exist teflon teflon does not exist does not exist teflon teflon L-Met (g/l) 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 T20 (g/l) 0.3 0.15 0.30 0.15 0.3 0.15 0.3 0.15 NaCl (g/l) 9 9 9 9 9 9 9 9 9 9 9 9 Toxin concentration (U/ml) 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
- COC represents a cyclic olefin copolymer
- COP represents a cyclic olefin polymer
- BIIR and CIIR stand for bromo and chloro butyl rubber (IIR), respectively.
- the material of the plunger stopper indicates the material of the rubber part.
- butyl rubber (IRR) is a copolymer of isobutylene and isoprene.
- Teflon coating refers to coating of BIIR or CIIR surfaces with FluroTec R film.
- L-Met, T20, Nacl, and Toxin represent the amounts of L-methionine, polysorbate 20, NaCl, and botulinum toxin type A components dissolved in water, ie, water for injection.
- the formulation engages the plunger rod assembly into the lumen of the barrel such that the stopper of the plunger seals the liquid formulation while in contact with the liquid formulation. Also, an outlet engaging portion of the distal end of the barrel sealingly engaged the capping device to close the open outlet.
- the syringe and the capping device are integrally formed, and the capping device is removed immediately before use. At this time, the liquid comes into contact with the rubber tip cap inside the capping device.
- the pre-filled syringe botulinum liquid formulation is in a state in which the syringe is not coupled to the injection needle and is coupled to the cappip device.
- the material of the syringe barrel is selected from COC and COP
- the stopper of the plunger is 2 concentrations of methionine and polysorbate 20 in 4 syringes selected from bromobutyl rubber and chlorobutyl rubber and its Teflon coating.
- a total of eight prefilled syringe botulinum liquid formulations were prepared differently.
- the prepared eight formulations ie, formulations A to H, were stored at 4° C. in a stable specimen storage room to measure the half lethal dose (LD 50 ) of mice at 0, 3, 6, 9, 12, 18, and 24 months of age.
- LD 50 half lethal dose
- LD 50 (recovery lethal value relative to initial value, %) designation Time tested (months) 0 3 6 9 12 18 24 A 100 99 94 89 83 77 75 B 100 96 90 90 92 89 85 C 100 96 75 95 86 76 73 D 100 102 75 84 86 77 77 E 100 100 73 91 97 79 77 F 100 96 76 80 80 78 78 G 100 97 99 - - - - H 100 79 92 - - - - - - - -
- the recovered lethal dose values of Formulations A to F at 24 months were measured to be 73% or more, but for Formulations G and H, no recovered lethal dose values were measured from 9 months.
- the barrel material is COP, the recovery titer was not measured from 9 months in this syringe.
- the eight prefilled syringe formulations A to H were stored in a stability chamber to measure the activity of BoNTA/LC at months 0, 3, 6, 9, 12, 18, and 24 months.
- SNAP25 self-made fragment consisting of 70 amino acid sequences was put into each well of a 96-well plate, and incubated at 2 to 8° C. for 16 hours.
- the SNAP25 fragment comprises at least 10 contiguous amino acid sequences including a cleavage site between amino acids 197 and 198.
- BONTA samples which are standard samples from which a quantitative curve can be obtained, are prepared using BoNTA standards (Innotox, Medytox), and in HEPES solution (Sigma) so that the result values of formulations A to H can be included in the range of the quantitative curve.
- Test samples were prepared by diluting BONTA. Each of the standard sample and test samples A to H was put into a well containing SNAP25 and reacted at room temperature for 1 hour. Next, an anti-SNAP25 polyclonal antibody (manufactured in-house) was added to each well and reacted at room temperature for 1 hour.
- the absorbance was measured at 450 nm in a plate reader (Microplate Reader, TECAN) to quantify the degree of color development according to the activity of BoNT/LC, and a quantitative curve was obtained using the absorbance value of a standard sample.
- the BoNT/LC activity of each sample was calculated.
- the activity of BoNT/LC at month 0 was set to 100%, and the tendency to change the activity of BoNT/LC obtained at each time point was expressed as a percentage.
- Table 3 is a table showing the endopeptidase activity of BoNTA contained in Formulations A to H according to the storage period.
- Protease activity (Recovered activity relative to initial value, %) designation Tested period (months) 0 3 6 9 12 18 24 A 100 106 109 103 121 123 141 B 100 102 105 103 119 115 130 C 100 107 111 101 127 107 124 D 100 100 104 94 121 101 118 E 100 99 107 92 119 99 111 F 100 108 104 96 130 111 130 G 100 107 112 - - - - H 100 100 109 - - - - - - - -
- each sample was placed in a 15 mL disposable tube at 3 mL or more and measured with a pH meter (METTLER TOLEDO). The pH of each sample was measured.
- Table 4 is a table showing the pH change of formulations A to H according to the storage period.
- formulations A to F were maintained between 6.8 and 7.4 at 24 months, while formulations G and H were maintained at pH 5.3 to 5.9 at 6 months when the activity was measured.
- Example 2 Stability of Botulinum Toxin Prefilled Liquid Syringe Formulation: Syringe with Barrel Made of Glass or COP Material
- the botulinum toxin prefilled liquid formulations in Table 5 below were prepared.
- the syringe is an HVD syringe listed in Table 1, with an inner diameter of 5.00 mm, an outer diameter of 9.40 mm, a barrel length of 80.0 mm, and a volume filled with a liquid formulation of 0.8 mL.
- the barrels of formulations I and J are products of POONGLIM Pharmatech Inc. (Catalog No., Art.69, Korea), and the barrels of formulations K and L are SiO2 Medical Products Inc. (Cat No., 850009-100-04, USA), and the barrels of formulations M and N are products of TERUMO (catalog number, PJ-B1L9BFTF1, Japan).
- the botulinum toxin is BTX1301 (API batch number) from Medytox, BoNTA.
- COC represents a cyclic olefin copolymer
- COP represents a cyclic olefin polymer.
- BIIR and CIIR stand for bromo and chloro butyl rubber (IIR), respectively.
- butyl rubber (IRR) is a copolymer of isobutylene and isoprene.
- L-Met, T20, Nacl, and toxin represent the amount of L-methionine, polysorbate 20, NaCl, and botulinum toxin type A components dissolved in water. The liquid containing these components had a pH of 6.0 to 7.0.
- the formulation engages the plunger rod assembly into the lumen of the barrel such that the stopper of the plunger seals the liquid formulation while in contact with the liquid formulation. Also, an outlet engaging portion of the distal end of the barrel sealingly engaged the capping device to close the open outlet. That is, the pre-filled syringe botulinum liquid formulation is in a state in which the syringe is not coupled to the injection needle and is coupled to the cappip device.
- the material of the syringe barrel is selected from glass and COP
- the plunger stopper is 3 types of syringes selected from bromobutyl rubber and i-coating. prefilled syringes of botulinum liquid formulations I to N were prepared.
- the prepared six formulations that is, I to N formulation samples were stored at 25° C. in a thermo-hygrostat (Binder) for experiments under accelerated test conditions.
- the samples were stored at 4°C in a stability specimen storage room.
- the half lethal dose (LD 50 ) of mice at 0, 2, 3, 4, and 6 months after storage was measured.
- the six prefilled syringe formulations I to N maintained their titers in the range of 86 to 108% relative to their initial titers.
- the six prefilled syringe formulations I to N were stored in a stability chamber to measure the activity of BoNTA/LC at 0, 2, 3, 4, and 6 months.
- SNAP25 self-made fragment consisting of 70 amino acid sequences was put into each well of a 96-well plate, and incubated at 2 to 8° C. for 16 hours.
- the SNAP25 fragment comprises at least 10 contiguous amino acid sequences including a cleavage site between amino acids 197 and 198.
- BONTA samples which are standard samples from which a quantitative curve can be obtained, are prepared using BoNTA standards (Innotox, Medytox), and in HEPES solution (Sigma) so that the result values of formulations A to H can be included in the range of the quantitative curve.
- Test samples were prepared by diluting BONTA. Each of the standard sample and test samples A to H was put into a well containing SNAP25 and reacted at room temperature for 1 hour. Next, an anti-SNAP25 polyclonal antibody (manufactured in-house) was added to each well and reacted at room temperature for 1 hour.
- the absorbance was measured at 450 nm in a plate reader (Microplate Reader, TECAN) to quantify the degree of color development according to the activity of BoNT/LC, and a quantitative curve was obtained using the absorbance value of a standard sample.
- the BoNT/LC activity of each sample was calculated.
- the activity of BoNT/LC at month 0 was set to 100%, and the tendency to change the activity of BoNT/LC obtained at each time point was expressed as a percentage.
- Table 7 is a table showing the endopeptidase activity of BoNTA contained in Formulations I to N according to the storage period.
- Protease activity (Recovered activity relative to initial value, %) designation Tested period (months) 0 2 3 4 6
- each sample was placed in a 15 mL disposable tube so as to be 3 mL or more, and the pH of each sample was measured with a pH meter (Mettler Toledo).
- Table 8 is a table showing the pH change of Formulations I to N according to the storage period. The time points are 0, 2, 4, and 6 months for accelerated condition experiments, and 0, 3, and 6 months for long-term preservation experiments.
- Formulation O containing human serum albumin but not containing L-Met and polysorbate 20 and Formulation P containing L-Met and polysorbate 20 instead of containing human serum albumin were prepared.
- the solvent is water
- Toxin is a BoNTA type product manufactured by Medytox.
- the HVD syringe is a syringe B of Table 1
- the barrel is made of COC material
- the plunger material is made of siliconized BIIR.
- mice Two prepared, i.e., O and P formulation samples were prefilled in each syringe with syringe formulations stored in a stability chamber, and half lethal dose (LD50) of mice at 0, 2, 3, 7, 14, 28, and 56 days. was measured.
- LD50 half lethal dose
- Samples 1 and 2 were serially diluted with water, respectively, and then administered intraperitoneally to 4-week-old female ICR mice weighing 17 to 22 g.
- the lethality was observed for each diluted sample for 3 days after administration, and the half lethal dose was calculated using the statistical program PROBIT.
- the half lethal dose at month 0 was set to 100%, and the tendency to change the half lethal dose obtained at each time point was expressed as a percentage. Shelf life was calculated using the Arrhenius equation (https://met.uk.com/medical-device-packaging-testing/4a-medical-accelerated-ageing) showing the relationship between the reaction rate constant and temperature. Calculated.
- Table 10 is a table showing the storage stability of the albumin-containing formulation O and the albumin-free formulation P as LD 50 values.
- STD Medytoxin strain (Medytoxin) as a standard sample
- normalization represents the relative titer when the data value is 100 at day 0, and N/A is the test result LD50 in the previous cycle. The value was so low as 20%, it was not meaningful to proceed with the test.
- the three prepared formulations i.e., standard sample (STD), O, and P formulations, lost their recovery titers on the 28th day of the test in the accelerated conditions of 56 days, that is, about 2 months, but the non-albumin formulation P at 28 days. A recovery titer of 86% and 52% at 56 days was maintained.
- samples were stored at 40° C., and samples were recovered at 0, 2, 5, 7, 14, 28, and 56 days.
- Albumin Formulation O and Albumin-Free Formulation P described in Table 9 were respectively filled into 1 ml of the SHOTT TopPac syringe and HVD syringe described in Section 1 of Example 1, i.e., the B syringe of Table 1, for a total of 4 prefilled syringes.
- Botulinum liquid formulations Q, R, S, and T i.e., four formulations were prepared.
- the plunger injection force according to the plunger movement speed of the syringe was measured using a MultiTest 2.5 (Mecmesin, UK) tensile compression device.
- the injection force is an average injection force.
- a 30 G needle was coupled to a syringe containing each of the four formulations.
- the syringe was fixed to the jig of the tensile compression device and the plunger rod was adjusted to be centered on the load cell of the device.
- the jig is the syringe holding part of the device.
- the speed value was entered in the program built into the device, and the device was operated by pressing the start button to perform the test.
- the above measurement distance is about 40 mm high when filling 1 mL because the HVD syringe has a small inner diameter and long length, and the TopPac syringe is filled to a height of about 30 mm when filling 1 mL, so it is 5 mm for safety when measuring injection force.
- the measurement distance was set to press the plunger from 0 to 35 mm for the HVD syringe and 0 to 25 mm for the TopPac syringe. After the measurement was completed, the sample was removed from the jig, and the measurement was repeated 3 times per sample to obtain the injection force result.
- Table 11 is a table showing the injection force according to the plunger moving speed.
- formulations R and T with HVD syringe had the same or higher injection force compared to formulations Q and S with TopPac syringe at low plunger movement rates of 10 and 50 mm/min, but 100 and At a high plunger movement speed of 200 mm/min, the injection force was lower compared to formulations Q and S with TopPac syringes.
- formulations R and T containing the HVD syringe had higher plunger compression force at low plunger travel speeds and lower plunger compression force at high plunger travel speeds, compared to formulations Q and S, including TopPac syringes.
- HVD syringes Formulations containing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
제형 명 | A | B | C | D | E | F | G | H |
배럴 재질 | COC | COC | COC | COC | COC | COC | COP | COP |
플런저 스토퍼 재질 | BIIR | BIIR | BIIR | BIIR | CIIR | CIIR | CIIR | CIIR |
플런저 스토퍼 코팅 | 없음 | 없음 | 테플론 | 테플론 | 없음 | 없음 | 테플론 | 테플론 |
L-Met(g/l) | 0.1 | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 |
T20(g/l) | 0.3 | 0.15 | 0.30 | 0.15 | 0.3 | 0.15 | 0.3 | 0.15 |
NaCl(g/l) | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
독소농도(U/ml) | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
물 채움 부피(ml) | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
LD50 (초기 값에 대한 회수 치사량 값, %) | |||||||
명칭 | 시험된 시간(월) | ||||||
0 | 3 | 6 | 9 | 12 | 18 | 24 | |
A | 100 | 99 | 94 | 89 | 83 | 77 | 75 |
B | 100 | 96 | 90 | 90 | 92 | 89 | 85 |
C | 100 | 96 | 75 | 95 | 86 | 76 | 73 |
D | 100 | 102 | 75 | 84 | 86 | 77 | 77 |
E | 100 | 100 | 73 | 91 | 97 | 79 | 77 |
F | 100 | 96 | 76 | 80 | 80 | 78 | 78 |
G | 100 | 97 | 99 | - | - | - | - |
H | 100 | 79 | 92 | - | - | - | - |
프로테아제 활성 (초기 값 대비 회수된 활성, %) | |||||||
명칭 | 시험된 기간(월) | ||||||
0 | 3 | 6 | 9 | 12 | 18 | 24 | |
A | 100 | 106 | 109 | 103 | 121 | 123 | 141 |
B | 100 | 102 | 105 | 103 | 119 | 115 | 130 |
C | 100 | 107 | 111 | 101 | 127 | 107 | 124 |
D | 100 | 100 | 104 | 94 | 121 | 101 | 118 |
E | 100 | 99 | 107 | 92 | 119 | 99 | 111 |
F | 100 | 108 | 104 | 96 | 130 | 111 | 130 |
G | 100 | 107 | 112 | - | - | - | - |
H | 100 | 100 | 109 | - | - | - | - |
pH | |||||||
명칭 | 시험된 기간(월) | ||||||
0 | 3 | 6 | 9 | 12 | 18 | 24 | |
A | 6.7 | 6.9 | 7.0 | 7.3 | 7.2 | 7.3 | 7.4 |
B | 6.8 | 7.1 | 7.1 | 7.3 | 7.3 | 7.3 | 7.3 |
C | 6.0 | 6.5 | 6.6 | 6.6 | 6.5 | 6.5 | 6.8 |
D | 6.1 | 6.5 | 6.5 | 6.5 | 6.5 | 6.6 | 6.8 |
E | 6.3 | 6.6 | 6.5 | 6.6 | 6.5 | 6.7 | 6.8 |
F | 6.2 | 6.6 | 6.5 | 6.6 | 6.7 | 6.7 | 6.6 |
G | 5.9 | 5.7 | 5.5 | - | - | - | - |
H | 5.9 | 5.6 | 5.3 | - | - | - | - |
제형 명 | I | J | K | L | M | N |
배럴 재질 | 유리 | 유리 | COP | COP | COP | COP |
플런저 스토퍼 재질 | BIIR | BIIR | BIIR | BIIR | i-coating | i-coating |
L-Met(g/l) | 0.05 | 0.1 | 0.05 | 0.1 | 0.05 | 0.1 |
T20(g/l) | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
NaCl(g/l) | 9 | 9 | 9 | 9 | 9 | 9 |
톡신농도(U/ml) | 40 | 40 | 40 | 40 | 40 | 40 |
물 채움 부피(ml/주사기) | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
LD50 (초기 값에 대한 회수 치사량 값, %) | |||||||
명칭 | 시험된 시간(월) | ||||||
0 | 2 | 3 | 4 | 6 | |||
I | 가속 | 100 | 97 | - | 87 | 89 | |
장기 | 100 | - | 93 | - | 94 | ||
J | 가속 | 100 | 98 | - | 86 | 89 | |
장기 | 100 | - | 89 | - | 94 | ||
K | 가속 | 100 | 100 | - | 90 | 97 | |
장기 | 100 | - | 92 | - | 97 | ||
L | 가속 | 100 | 105 | - | 97 | 102 | |
장기 | 100 | - | 100 | - | 108 | ||
M | 가속 | 100 | 100 | - | 92 | 91 | |
장기 | 100 | - | 96 | - | 102 | ||
N | 가속 | 100 | 93 | - | 85 | 86 | |
장기 | 100 | - | 90 | - | 93 |
프로테아제 활성 (초기 값 대비 회수된 활성, %) | ||||||
명칭 | 시험된 기간(월) | |||||
0 | 2 | 3 | 4 | 6 | ||
I | 가속 | 100 | 81 | - | 54 | 53 |
장기 | 100 | - | 79 | - | 80 | |
J | 가속 | 100 | 68 | - | 67 | 65 |
장기 | 100 | - | 73 | - | 83 | |
K | 가속 | 100 | 76 | - | 63 | 70 |
장기 | 100 | - | 84 | - | 83 | |
L | 가속 | 100 | 78 | - | 82 | 78 |
장기 | 100 | - | 85 | - | 90 | |
M | 가속 | 100 | 82 | - | 79 | 81 |
장기 | 100 | - | 92 | - | 96 | |
N | 가속 | 100 | 86 | - | 83 | 84 |
장기 | 100 | - | 92 | - | 94 |
pH | ||||||
명칭 | 시험된 기간(월) | |||||
0 | 2 | 3 | 4 | 6 | ||
I | 가속 | 6.5 | 7.8 | 7.3 | 7.9 | |
장기 | 6.5 | 7.6 | 7.7 | |||
J | 가속 | 6.7 | 7.8 | 7.4 | 7.8 | |
장기 | 6.7 | 7.6 | 7.8 | |||
K | 가속 | 6.6 | 7.6 | 7.2 | 7.6 | |
장기 | 6.6 | 7.4 | 7.5 | |||
L | 가속 | 6.5 | 7.5 | 7.1 | 7.4 | |
장기 | 6.5 | 7.2 | 7.4 | |||
M | 가속 | 6.2 | 7.4 | 6.7 | 7.3 | |
장기 | 6.2 | 7.2 | 7.3 | |||
N | 가속 | 5.9 | 7.3 | 6.7 | 7.1 | |
장기 | 5.9 | 7.1 | 7.1 |
명칭 | NaCl | L-Met | Tween20 | HSA | Toxin |
0.9% | 0.02% | 0.015% | 0.02% | (30 Unit) | |
O | + | - | - | + | + |
P | + | + | + | - | + |
안정성 시험 기간(일) | 0 | 2 | 5 | 7 | 14 | 28 | 56 | |
LD50 (%) | STD | 97 | 97 | 103 | 101 | 103 | 105 | 96 |
O | 92 | 68 | 50 | 48 | 25 | N/A | N/A | |
P | 109 | 98 | 91 | 94 | 86 | 86 | 52 | |
정규화 | O | 100 | 74 | 55 | 53 | 28 | N/A | N/A |
P | 100 | 90 | 84 | 87 | 79 | 79 | 48 | |
유효기간 (일) | 0 | 30 | 60 | 90 | 170 | 340 | 680 |
명칭 | Q | R | S | T | |
제제 | O | O | P | P | |
주사기 타입 | TopPac 1ml | HVD 1ml | TopPac 1ml | HVD 1ml | |
평균 플런저 주입력(N) |
10 mm/min | 1.45 | 1.68 | 1.13 | 1.35 |
50 mm/min | 2.72 | 2.72 | 2.52 | 2.53 | |
100 mm/min | 4.24 | 3.79 | 3.08 | 3.30 | |
200 mm/min | 6.25 | 4.72 | 4.84 | 4.39 |
Claims (15)
- 주사기 배럴, 플런저 로드 및 플런저 스토퍼를 포함하는 주사기, 및상기 주사기 내에 충전되어 있는 보툴리눔 독소 액상 제제를 포함하고,상기 보툴리눔 독소 액상 제제가 토출되는 속도의 증가에 따라 상기 플런저 로드의 말단에 작용하는 힘의 증가량이 감소하는 보툴리눔 독소 사전충전된 주사기 제형.
- 청구항 1에 있어서, 상기 주사기 배럴의 내경에 대한 길이의 비율이 10 내지 22인 것인 제형.
- 청구항 2에 있어서, 상기 주사기 배럴의 내경이 3.5 내지 6.5 mm이고, 길이가 60 내지 100 mm인 것인 제형.
- 청구항 1에 있어서, 상기 주사기 배럴의 재질이 유리, COC, 또는 COP인 것인 제형.
- 청구항 1에 있어서, 상기 플런저 스토퍼의 재질이 이소프렌 고무(IS), 부타디엔 고무(BR), 부틸 고무, 할로겐화 부틸 고무, 스티렌-부타디엔 고무, 또는 이들의 혼합물인 것인 제형.
- 청구항 1에 있어서, 상기 보툴리눔 독소 액상 제제는 알부민을 함유하지 않은 것인 제형.
- 청구항 1에 있어서, 상기 보툴리눔 독소 액상 제제는 동물성 성분을 함유하지 않은 것인 제형.
- 청구항 6 또는 7에 있어서, 상기 보툴리눔 독소 액상 제제는 보툴리눔 독소, 아미노산, 계면활성제 및 등장화제를 포함하는 것인 제형.
- 청구항 8에 있어서, 상기 아미노산은 메티오닌인 것인 제형.
- 청구항 8에 있어서, 상기 계면활성제는 폴리소르베이트 20, 폴리소르베이트 40, 폴리소르베이트 60, 폴리소르베이트 80, 또는 폴록사머인 것인 제형.
- 청구항 6 또는 8에 있어서, 보툴리눔 독소 액상 제제는 pH를 5.5 내지 7.5로 유지하도록 하는 완충제를 더 함유하는 것인 제형.
- 청구항 11에 있어서, 상기 완충제는 시트레이트, 히스티딘, HEPES, 아르기닌, 아세트산, 인산, 이들의 염, 또는 이들의 혼합물인 것인 제형.
- 청구항 1 내지 8 중 어느 한 항에 있어서, 상기 보툴리눔 독소 액상 제제는 가속 시험 조건인 25℃에서, 2, 4, 또는 6개월 동안 보관하였을 때 초기 값 대비 80 내지 125%의 LD50 역가 회수율을 나타내는 것인 제형.
- 청구항 1 내지 8 중 어느 한 항에 있어서, 상기 보툴리눔 독소 액상 제제는 가속 시험 조건인 25℃에서, 2, 4, 또는 6개월 동안 보관하였을 때 초기 값 대비 80 내지 125%의 프로테아제 활성 회수율을 나타내는 것인 제형.
- 청구항 1 내지 8 중 어느 한 항에 있어서, 상기 보툴리눔 독소 액상 제제는 가속 시험 조건인 25℃에서, 2, 4, 또는 6개월 동안 보관하였을 때 초기 값 대비 ± 1.0 이내의 pH 변동을 갖는 것인 제형.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21784347.3A EP4122448A4 (en) | 2020-04-08 | 2021-03-31 | INJECTABLE FORMULATION PRE-FILLED WITH BOTULINUM TOXIN WHICH FACILITATES THE REGULATION OF THE DISCHARGE RATE AND IS STABLE |
CN202180026182.8A CN115397399A (zh) | 2020-04-08 | 2021-03-31 | 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型 |
JP2022561492A JP2023521123A (ja) | 2020-04-08 | 2021-03-31 | 吐出速度調節が容易であり、安定したボツリヌム毒素事前充填の注射器剤形 |
BR112022020327A BR112022020327A2 (pt) | 2020-04-08 | 2021-03-31 | Formulação de seringa pré-carregada com toxina botulínica |
US17/995,428 US20230165946A1 (en) | 2020-04-08 | 2021-03-31 | Botulinum toxin pre-filled injectable formulation that facilitates discharge rate control and is stable |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0042966 | 2020-04-08 | ||
KR10-2020-0042967 | 2020-04-08 | ||
KR1020200042967A KR102404217B1 (ko) | 2020-04-08 | 2020-04-08 | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 |
KR10-2020-0042962 | 2020-04-08 | ||
KR1020200042966A KR20210125358A (ko) | 2020-04-08 | 2020-04-08 | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 |
KR1020200042962A KR20210125354A (ko) | 2020-04-08 | 2020-04-08 | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021206360A1 true WO2021206360A1 (ko) | 2021-10-14 |
Family
ID=78023425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/003989 WO2021206360A1 (ko) | 2020-04-08 | 2021-03-31 | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230165946A1 (ko) |
EP (1) | EP4122448A4 (ko) |
JP (1) | JP2023521123A (ko) |
CN (1) | CN115397399A (ko) |
BR (1) | BR112022020327A2 (ko) |
WO (1) | WO2021206360A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11975047B1 (en) * | 2022-10-28 | 2024-05-07 | Ani Pharmaceuticals, Inc. | Methods for storing and warming purified corticotropin compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058472A2 (en) * | 2000-02-08 | 2001-08-16 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
KR20160113597A (ko) * | 2013-12-12 | 2016-09-30 | (주)메디톡스 | 새로운 보툴리눔 독소 제제의 오래 지속되는 효과 |
KR101753242B1 (ko) * | 2008-12-31 | 2017-07-20 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
KR20170109051A (ko) * | 2015-02-03 | 2017-09-27 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소 사전충전된 용기 |
KR20190022460A (ko) * | 2016-06-22 | 2019-03-06 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소 사전충전된 주사기 시스템 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1596909A2 (en) * | 2003-02-27 | 2005-11-23 | Baxter International Inc. | Piston assembly for syringe |
KR101087017B1 (ko) * | 2007-07-10 | 2011-12-09 | (주)메디톡스 | 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물 |
WO2009158145A2 (en) * | 2008-05-30 | 2009-12-30 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
EP2776603B1 (en) * | 2011-11-11 | 2019-03-06 | SiO2 Medical Products, Inc. | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS |
ES2788999T3 (es) * | 2014-12-23 | 2020-10-23 | Merz Pharma Gmbh & Co Kgaa | Envase prellenado de toxina botulínica |
-
2021
- 2021-03-31 US US17/995,428 patent/US20230165946A1/en active Pending
- 2021-03-31 EP EP21784347.3A patent/EP4122448A4/en active Pending
- 2021-03-31 WO PCT/KR2021/003989 patent/WO2021206360A1/ko unknown
- 2021-03-31 BR BR112022020327A patent/BR112022020327A2/pt unknown
- 2021-03-31 JP JP2022561492A patent/JP2023521123A/ja active Pending
- 2021-03-31 CN CN202180026182.8A patent/CN115397399A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058472A2 (en) * | 2000-02-08 | 2001-08-16 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
KR101753242B1 (ko) * | 2008-12-31 | 2017-07-20 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
KR20160113597A (ko) * | 2013-12-12 | 2016-09-30 | (주)메디톡스 | 새로운 보툴리눔 독소 제제의 오래 지속되는 효과 |
KR20170109051A (ko) * | 2015-02-03 | 2017-09-27 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소 사전충전된 용기 |
KR20190022460A (ko) * | 2016-06-22 | 2019-03-06 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소 사전충전된 주사기 시스템 |
Non-Patent Citations (2)
Title |
---|
See also references of EP4122448A4 |
WR PEARSONDJ LIPMAN, PNAS, vol. 85, 1988, pages 2444 - 2448 |
Also Published As
Publication number | Publication date |
---|---|
US20230165946A1 (en) | 2023-06-01 |
CN115397399A (zh) | 2022-11-25 |
BR112022020327A2 (pt) | 2022-12-13 |
EP4122448A1 (en) | 2023-01-25 |
JP2023521123A (ja) | 2023-05-23 |
EP4122448A4 (en) | 2024-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11219717B2 (en) | Botulinum toxin prefilled plastic syringe | |
KR102486484B1 (ko) | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 | |
US20210316077A1 (en) | Botulinum toxin prefilled container | |
CN109069755B (zh) | 肉毒杆菌毒素预填充式注射器系统 | |
WO2021206360A1 (ko) | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 | |
KR20210125354A (ko) | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 | |
KR20210125358A (ko) | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 | |
BR112017013764B1 (pt) | Seringa de vidro pré-carregada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21784347 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022561492 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022020327 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021784347 Country of ref document: EP Effective date: 20221020 |
|
ENP | Entry into the national phase |
Ref document number: 112022020327 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221007 |